Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
24 January 2023 - 1:00AM
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune
testing solutions, announced today that Tina S. Nova, Ph.D. has
been elected as Executive Chair of the Exagen Board of Directors,
effective January 19, 2023. Dr. Nova succeeds Brian Birk, who has
served as Chair of the Board of Directors at Exagen since 2018, and
who will remain a member of the Board.
Dr. Nova currently serves as President of Veracyte's (Nasdaq:
VCYT) U.S. CLIA business where she leads all aspects of the
company’s broad menu of diagnostic laboratory tests. She previously
held the position of President & CEO of Decipher Biosciences
until March 2021, when Veracyte purchased the organization for $600
million. She has held numerous leadership roles in the
life science industry, which include CEO of Molecular Stethoscope
and SVP & General Manager of Oncology at Illumina.
Dr. Nova was the co-founder, President & CEO of Genoptix, which
was purchased by Novartis AG for $470 million in 2011. She has also
held senior positions with Nanogen, Inc., Ligand Pharmaceuticals,
Inc. and Hybritech.
“I am excited to welcome Tina as Executive Chair at
Exagen. Her broad experience with innovative healthcare
companies and leadership in growing organizations with proprietary
technology will be invaluable to Exagen as we look to expand our
position as the premier provider of autoimmune testing solutions,”
said John Aballi, President and CEO of Exagen. “I have
had the pleasure of working with Tina for almost 15 years, and I’m
thrilled to work closely with her again as we continue to shape the
future of Exagen.”
“I am honored to have been elected Executive Chair and I’m
excited to take on this additional leadership role at Exagen,” said
Dr. Nova. “I also want to thank Brian Birk, who served
as the company’s Chair since 2018. Brian was
instrumental in growing the organization into a leader in
autoimmune testing and I am pleased that he will remain a
member of the Board.”
Dr. Nova currently serves on the Board of Azenta (Nasdaq: AZTA)
and previously served on the Board of Directors of Veracyte and
Arena Pharmaceuticals. Dr. Nova holds a Ph.D. in
Biochemistry from the University of California, Riverside and a
B.S. in Biological Sciences from the University of California,
Irvine.
About Exagen
Exagen (Nasdaq: XGN) is a leading provider of autoimmune
diagnostic, prognostic, and monitoring testing
solutions. Exagen is a patient focused, discovery driven
organization built on the success of AVISE testing and is investing
in its product pipeline to support patients throughout their
autoimmune diagnosis and treatment journeys. The goal
at Exagen is to assist patients, physicians, and payors
by enabling precision medicine. Exagen is located
in San Diego County with clinical and research and
development laboratories in Vista, CA.
For more information, please visit Exagen.com and
follow @ExagenInc on Twitter.
Forward-Looking Statements
Exagen cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. These statements are based on Exagen’s
current beliefs and expectations. Such forward-looking statements
include, but are not limited to, statements
regarding: Exagen's goals and strategies; the potential
utility and effectiveness of Exagen's services and
testing solutions that are currently available or in its
development pipeline; the expected benefits of Dr. Nova’s position
with Exagen; and Exagen's potential growth and
success and its ability to continue to grow and succeed. The
inclusion of forward-looking statements should not be regarded as a
representation by Exagen that any of its plans will be
achieved. Actual results may differ from those set forth in this
press release due to the risks and uncertainties inherent in
Exagen’s business, including, without limitation: the COVID-19
pandemic may continue to adversely affect its business, financial
condition and results of operations, including as a result of
slowdown in its operations as well as those of its suppliers and
courier services, impeding patient movement and interruptions to
healthcare services causing a decrease in test volumes, disruptions
to the supply chain of material needed for its tests causing an
increase in cost per test, its sales and commercialization
activities and its ability to receive specimens and perform or
deliver the results from its tests, delays in reimbursement and
coverage decisions from Medicare and third-party payors and in
interactions with regulatory authorities, and delays in ongoing and
planned clinical trials involving its tests; Exagen’s commercial
success depends upon attaining and maintaining significant market
acceptance of its testing products and promoted therapeutics among
rheumatologists, patients, third-party payors and others in the
medical community; Exagen’s ability to successfully execute on its
business strategies; third-party payors not providing coverage and
adequate reimbursement for Exagen’s testing products or promoted
therapeutics, including Exagen's ability to collect funds
due; Exagen’s ability to obtain and maintain intellectual property
protection for its testing products; regulatory developments
affecting Exagen’s business; and other risks described in Exagen’s
prior press releases and Exagen’s filings with the Securities
and Exchange Commission ("SEC"), including under the heading
“Risk Factors” in Exagen’s Annual Report on Form 10-K for the year
ended December 31, 2021 and any subsequent filings with
the SEC. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and Exagen undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date hereof. All forward-looking statements are
qualified in their entirety by this cautionary statement, which is
made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995.
Contacts:Investors
RelationsExagen Inc.Ryan
Douglasrdouglas@exagen.com 760.560.1525
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com760.477.5514
Azenta (NASDAQ:AZTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Azenta (NASDAQ:AZTA)
Historical Stock Chart
From Apr 2023 to Apr 2024